Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.990 -0.070 (-0.77%)
Streaming Delayed Price Updated: 2:18 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
News headline image
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream' ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Earnings Preview For Compass Pathways ↗
 
Via Benzinga
News headline image
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America? ↗
 
Via Benzinga
News headline image
Penny Power Players: 3 Stocks to Watch in the Microcap Arena ↗
Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out. 
Via InvestorPlace
News headline image
Mental Health Mavericks: 3 Stocks Changing the Game ↗
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
News headline image
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. ↗
The lofty target is closer to being within reach than it may seem at first. 
Via The Motley Fool
News headline image
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex ↗
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... 
Via Talk Markets
News headline image
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
 
Via Benzinga
News headline image
Why Is MindMed (MNMD) Stock Up 8% Today? ↗
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers. 
Via InvestorPlace
News headline image
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. 
Via Talk Markets
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
News headline image
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
News headline image
New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy ↗
Study found that suggestibility did not predict response to psilocybin therapy for MDD patients, challenging concerns about placebo effects. 
Via Benzinga
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
News headline image
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. 
Via Talk Markets
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
News headline image
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution ↗
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024. 
Via InvestorPlace
News headline image
3 Big New Catalysts for Psychedelics Stocks in 2024 ↗
This could be the year that psychedelics stocks start to fly. 
Via The Motley Fool
News headline image
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
News headline image
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
News headline image
Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research ↗
Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models  
Via Benzinga
News headline image
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect ↗
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 1, 2024 ↗
 
Via Benzinga
News headline image
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Up In December; Down YTD ↗
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
News headline image
Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism' ↗
The question of whether psychedelic treatments always require psychotherapy is one hotly debated among researchers, and answers -as well as backstories- vary throughout the whole spectrum. 
Via Benzinga
News headline image
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.